When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and ... Show More
Yesterday
Secrets, Chips and Spycraft: The Nvidia C.E.O. Scandal
Over the weekend, Jensen Huang, the chief executive and co-founder of Nvidia — which makes the chips that power artificial intelligence — admitted to having an affair with a woman who has been determined by U.S. officials to be a spy. That revelation came after The New York Times ... Show More
31m 44s
Nov 9
After a Crushing Defeat, Trump Doubles Down
After a stinging rebuke last week at the polls, President Trump announced that he would elevate Stephen Miller — a driving force behind some of the most polarizing policies of Mr. Trump’s second term — to chief of staff.Maggie Haberman and Jonathan Swan, White House reporters for ... Show More
31m 14s
Mar 2023
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ... Show More
13m 46s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s
Apr 2023
Audio long read: Conquering Alzheimer’s — a look at the therapies of the future
Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ... Show More
17m 31s